A Randomized Multicenter Phase II Study of Gemcitabine/Platinum/Cetuximab Versus Gemcitabine/Platinum as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
tumor response per treatment arm
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
United States: Food and Drug Administration
CA225-100
NCT00112346
January 2005
December 2006
Name | Location |
---|---|
Local Institution | Chicago, Illinois |
Local Institution | Indianapolis, Indiana |
Local Institution | Baltimore, Maryland |
Local Institution | Bronx, New York |
Local Institution | Cincinnati, Ohio |
Local Institution | Portland, Oregon |
Local Institution | Vancouver, Washington |
Local Institution | Birmingham, Alabama |
Local Institution | Corona, California |
Local Institution | Aurora, Colorado |
Local Institution | Fort Lauderdale, Florida |
Local Institution | Springfield, Massachusetts |
Local Institution | Albuquerque, New Mexico |
Local Institution | Wilmington, North Carolina |
Local Institution | North Charleston, South Carolina |
Local Institution | Austin, Texas |
Local Institution | Rome, Georgia |
Local Institution | Bismarck, North Dakota |
Local Institution | Honolulu, Hawaii |
Local Institution | Anchorage, Alaska |